Numab

Numab AG is a Swiss biotechnology company involved in the invention of antibody-based therapeutics.

Numab AG is a Swiss biotechnology company involved in the invention of antibody-based therapeutics. The company engineers molecules with tailored pharmacological properties such as multi-specific products with short or long half-live. Numab AG has created a pipeline of proprietary antibody-based programs and offers to discover innovative antibody-based therapeutics on behalf of partners in the pharmaceutical industry. They design and develop a new class of powerful therapeutics for the treatment of severe diseases. Their plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.